Saudi Chemical Company Holding announced on May 10, 2026 the latest developments regarding its subsidiary AJA Pharmaceutical Industries Company's manufacturing plant. The company has completed the trial phase and commenced initial operation of the fourth production line—an advanced sterile injectables line—following successful production of first experimental batches in accordance with approved standards. This development represents an initial operational phase aimed at enhancing manufacturing capabilities in the pharmaceutical sector and contributing to the localization of high value-added pharmaceutical manufacturing, aligning with Saudi Vision 2030 objectives. The company clarified that this phase does not constitute commencement of commercial production, with no material change in project costs compared to previous announcements, though positive impact is expected once commercial operations begin.

Original announcement:

Important Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.